Clinical Scenario:
A 14-year-old girl with a known history of rheumatic heart disease (diagnosed at age 9, on irregular secondary prophylaxis) presents with palpitations and easy fatigability for the past 2 weeks. She denies fever or joint pain. On examination, pulse is irregularly irregular at 130/min, and there is a loud S1 with a mid-diastolic rumble at the apex. ECG shows absent P waves with irregular RR intervals, consistent with atrial fibrillation. Echocardiography reveals severe mitral stenosis (valve area 0.9 cm²) with left atrial enlargement; no intracardiac thrombus is seen.
What is the most appropriate anticoagulant to prevent thromboembolism in this patient?
Options:
A. Apixaban
B. Aspirin plus clopidogrel
C. Dabigatran
D. Rivaroxaban
E. Warfarin
Correct answer & Explanation:
Key: E
Explanation:
This patient has “valvular atrial fibrillation” — defined as AF occurring in the setting of moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve. This is a distinct clinical entity from non-valvular AF, and the choice of anticoagulant differs significantly.
Why Warfarin (E) is correct:
- Per the 2020 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease and the 2021 ESC/EACTS Guidelines, vitamin K antagonists (warfarin) are the anticoagulant of choice in patients with AF associated with moderate/severe mitral stenosis.
- Direct oral anticoagulants (DOACs) were not studied in — and are explicitly contraindicated for — patients with rheumatic mitral stenosis or mechanical valves, because the thrombogenic mechanism (atrial stasis from mechanical/structural obstruction) differs from that of non-valvular AF.
- The RE-ALIGN trial (dabigatran vs. warfarin in mechanical valve patients) was terminated early due to excess thromboembolic and bleeding events with dabigatran, reinforcing that DOACs are unsafe in this specific population.
Why other options are wrong:
- A. Apixaban — A DOAC; excluded from pivotal trials in valvular AF (e.g., ARISTOTLE excluded significant MS); not recommended.
- B. Aspirin plus clopidogrel — Antiplatelet therapy is inferior to anticoagulation for stroke prevention in AF and is not guideline-recommended for valvular AF.
- C. Dabigatran — Directly shown to be harmful compared to warfarin in valvular heart disease (RE-ALIGN trial); contraindicated.
- D. Rivaroxaban — Another DOAC; same rationale as apixaban — not validated/recommended in valvular AF.
Guidelines referenced:
- Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143:e72–e227.
- Vahanian A, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.
- Eikelboom JW, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (RE-ALIGN). N Engl J Med. 2013;369:1206–1214.
